-
公开(公告)号：US20210187105A1
公开(公告)日：2021-06-24
申请号：US17139772
申请日：2020-12-31
Applicant: Baxalta Incorporated , Baxalta GmbH
Inventor： Randolf Kerschbaumer , Dirk Voelkel , Friedrich Scheiflinger , Hartmut Ehrlich
IPC: A61K39/395 , A61K31/56 , A61K31/58 , A61K31/573 , C07K16/24
Abstract: The present invention pertains to anti-MIF antibodies, in particular their use in combination with glucocorticoids, in the treatment of glucocorticoid receptive diseases.
-
公开(公告)号：US20210128701A1
公开(公告)日：2021-05-06
申请号：US16592554
申请日：2019-10-03
Applicant: Baxalta Incorporated , Baxalta GmbH , Katholieke Universiteit Leuven
Inventor： Barbara PLAIMAUER , Hanspeter Rottensteiner , Friedrich Scheiflinger , Simon De Meyer , Frederik Denorme
Abstract: Provided herein are methods for recanalization of occluded blood vessels in a subject having an infarction. The method includes a step of administering to the subject a therapeutically effective amount of isolated ADAMTS13 protein at particular dosages and ranges of times after detection of the infarction. As described herein, ADAMTS13 advantageously recanalizes occluded blood vessels and reduces infarction size, even when administered a prolonged period after stable occlusion. Accordingly, such methods and compositions are useful for the treatment of infractions caused by blood vessel occlusion.
-
公开(公告)号：US20190225648A1
公开(公告)日：2019-07-25
申请号：US16359763
申请日：2019-03-20
Applicant: Baxalta Incorporated , Baxalta GmbH
Inventor： Friedrich Scheiflinger , Michael Dockal
IPC: C07K7/06 , C07K7/08 , C07K1/04 , C07K14/755
Abstract: A peptide or peptide derivative comprising: (i) WDLYFEIVW (SEQ ID NO:1); or (ii) a variant amino acid sequence comprising one, two, three or four L-amino acid substitutions in WDLYFEIVW (SEQ ID NO: 1); or (iii) the retro-inverso variant of the peptide or peptide derivative of either one of parts (i) and (ii), wherein said peptide or peptide derivative has procoagulant activity. A peptide or peptide derivative comprising: (i) an amino acid sequence comprising imfwydcye; or (ii) a variant amino acid sequence comprising one, two, three, four, five or six amino acid substitutions in imfwydcye, wherein said peptide or peptide derivative has procoagulant activity.
-
公开(公告)号：US20180072784A1
公开(公告)日：2018-03-15
申请号：US15681074
申请日：2017-08-18
Applicant: Baxalta GmbH , Baxalta Incorporated
Inventor： Michael DOCKAL , Hartmut Ehrlich , Friedrich Scheiflinger , Ulf Reimer , Ulrich Reineke , Thomas Polakowski , Eberhard Schneider
CPC classification number: C07K14/4703 , A61K38/00 , A61K47/551 , A61K47/557 , A61K47/60 , C07K7/08 , C07K14/001 , Y02A50/463
Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.
-
5.发明申请公开(公告)号：US20170233455A1
公开(公告)日：2017-08-17
申请号：US15349930
申请日：2016-11-11
Applicant: Baxalta Incorporated , Baxalta GmbH
Inventor： Falko-Günter Falkner , Franziska Horling , Johannes Lengler , Hanspeter Rottensteiner , Friedrich Scheiflinger
IPC: C07K14/755 , A61K48/00 , C12N15/86
CPC classification number: C07K14/755 , A61K48/0008 , A61K48/0058 , A61K48/0066 , C12N15/86 , C12N2750/14143 , C12N2800/22 , C12N2840/007
Abstract: The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A.
-
Patent Agency Ranking
6.发明申请公开(公告)号：US20170226487A1
公开(公告)日：2017-08-10
申请号：US15409032
申请日：2017-01-18
Applicant: Baxalta GmbH , Baxalta Incorporated
Inventor： Friedrich Scheiflinger , Ernst Boehm
CPC classification number: C12N9/0093 , C12N9/0006 , C12N9/644 , C12Y117/00 , C12Y304/21022
Abstract: The present invention relates to a host organism containing recombinant nucleic acids coding for the vitamin K reductase complex subunit 1 (VKORC1) and recombinant nucleic acids coding for a vitamin K dependent (VKD) protein, wherein both the recombinant VKORC1 and the recombinant VKD protein are expressed in said host organism. Further, the present invention relates to a cell culture system comprising cells which contain said recombinant nucleic acids and to methods for improving the productivity of recombinant VKD protein expression in a host organism being cultured in suitable systems.
-
7.发明申请公开(公告)号：US20170226188A1
公开(公告)日：2017-08-10
申请号：US15349940
申请日：2016-11-11
Applicant: Baxalta Incorporated , Baxalta GmbH
Inventor： Falko-Günter Falkner , Franziska Horling , Johannes Lengler , Hanspeter Rottensteiner , Friedrich Scheiflinger
IPC: C07K14/755 , C12N7/00 , C12N15/86
CPC classification number: C07K14/755 , A61K38/00 , C12N7/00 , C12N15/86 , C12N2750/14143 , C12N2800/22 , C12N2840/007
Abstract: The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A.
-
公开(公告)号：US20170035835A1
公开(公告)日：2017-02-09
申请号：US15242002
申请日：2016-08-19
Applicant: BAXALTA INCORPORATED , BAXALTA GMBH
Inventor： Michael Dockal , Thomas Polakowski , Frank Osterkamp , Rudolf Hartmann , Matthias Paschke , Bettina Hartlieb , Friedrich Scheiflinger
CPC classification number: A61K38/10 , A61K38/00 , A61K47/60 , C07K7/08 , C07K14/745
Abstract: The invention provides peptides, including peptides that bind and, optionally, inhibit Protein S, and compositions thereof. The peptides may be used to, e.g., inhibit Protein S activity, enhance thrombin formation in a subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify Protein S, and identify a Protein S binding compound.
Abstract translation: 本发明提供肽，包括结合并任选地抑制蛋白S的肽及其组合物。 肽可以用于例如抑制蛋白S活性，增强受试者中的凝血酶形成，增加受试者中的血块形成，治疗受试者的血液凝固障碍，纯化蛋白S，并鉴定蛋白S结合化合物。
-
公开(公告)号：US10822376B2
公开(公告)日：2020-11-03
申请号：US16359763
申请日：2019-03-20
Applicant: Baxalta Incorporated , Baxalta GmbH
Inventor： Friedrich Scheiflinger , Michael Dockal
IPC: C07K7/06 , C07K14/755 , C07K7/08 , C07K1/04 , A61K38/00
Abstract: A peptide or peptide derivative comprising: (i) WDLYFEIVW (SEQ ID NO:1); or (ii) a variant amino acid sequence comprising one, two, three or four L-amino acid substitutions in WDLYFEIVW (SEQ ID NO: 1); or (iii) the retro-inverso variant of the peptide or peptide derivative of either one of parts (i) and (ii), wherein said peptide or peptide derivative has procoagulant activity. A peptide or peptide derivative comprising: (i) an amino acid sequence comprising imfwydcye; or (ii) a variant amino acid sequence comprising one, two, three, four, five or six amino acid substitutions in imfwydcye, wherein said peptide or peptide derivative has procoagulant activity.
-
公开(公告)号：US10800816B2
公开(公告)日：2020-10-13
申请号：US15815347
申请日：2017-11-16
Applicant: Baxalta GmbH , Baxalta Incorporated
Inventor： Michael Dockal , Rudolf Hartmann , Friedrich Scheiflinger , Frank Osterkamp , Thomas Polakowski , Ulrich Reineke
Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. Peptide complexes also are provided. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.
-
-
-
-
-
-
-
-
-
Search Results
41
records
(took 0.028 seconds)
